OnKure Therapeutics
OKUR
49 hedge funds and large institutions have $25.8M invested in OnKure Therapeutics in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
4% more funds holding
Funds holding: 47 → 49 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9.63% less ownership
Funds ownership: 93.69% → 84.06% (-9.6%)
49% less capital invested
Capital invested by funds: $50.1M → $25.8M (-$24.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Acorn Capital Advisors
New York
|
+$3.67M |
| 2 |
SC
Shay Capital
New York
|
+$1.65M |
| 3 |
CF
Cantor Fitzgerald
New York
|
+$1.41M |
| 4 |
BlackRock
New York
|
+$1.25M |
| 5 |
HCM
Highbridge Capital Management
New York
|
+$589K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.9M |
| 2 |
PA
Perceptive Advisors
New York
|
-$4.32M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.54M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.09M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$901K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
51
Perceptive Advisors
New York
| – | -$4.32M | -1,004,439 | Closed |
|
|
SB
52
Samsara BioCapital
Palo Alto,
California
| – | -$3.54M | -824,155 | Closed |
|
|
IC
53
Ikarian Capital
Dallas,
Texas
| – | -$1.09M | -253,754 | Closed |
|
|
BFM
54
Boothbay Fund Management
New York
| – | -$335K | -78,021 | Closed |
|
55
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$80.3K | -18,663 | Closed |
|
OKUR Hedge Fund Activity: Q2 2025 in Review
49 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2025, worth a combined $25.8M — down 49% from $50.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OKUR positions and 6 closed out — a net gain of 2 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Acorn Capital Advisors, adding an estimated $3.67M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $7.9M sold.
- 49 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2025, up from 47 in Q1 2025.
- Funds reported $25.8M of OnKure Therapeutics stock for Q2 2025, down 49% quarter-over-quarter.
- 8 funds opened new OnKure Therapeutics positions in Q2 2025 and 6 closed out, a net change of +2 holders.
- The largest OnKure Therapeutics buyer in Q2 2025 was Acorn Capital Advisors, an estimated $3.67M added.
- The largest OnKure Therapeutics seller in Q2 2025 was Cormorant Asset Management, an estimated $7.9M sold.
Based on aggregated 13F filings for Q2 2025.